Press release
Samsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
Read moreCreating the future in peptides
We lead innovation in peptide API’s to the benefit of millions of patients
Contact usMarket leader in peptide API manufacturing and services
PolyPeptide is a Contract Development & Manufacturing Organization (CDMO) supporting pharmaceutical and biotech companies in the development and manufacturing of proprietary and generic active pharmaceutical ingredients (API).
PolyPeptide delivers +42% growth in H1 2026 and improved EBITDA margin; 2026 full-year guidance updated, now expecting 25-30% revenue growth and high-teens EBITDA margin
13 Aug 2026 - Baar, 13 August 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced its H1 2026 results, updated […]
Read moreSamsung Biologics announces tender offer to acquire PolyPeptide Group AG for CHF 44.31 per share
20 Jul 2026 - Baar, 20 July 2026 – PolyPeptide Group AG (SIX: PPGN), a specialized global CDMO for peptide-based active pharmaceutical ingredients, today announced Samsung Biologics’ tender offer to […]
Read more